Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • M.D., University of Miami 1982
• 

  Previous Appointments & Affiliations

  • Associate Professor of Neurology, Neurology, MS & Neuroimmunology, Neurology 2013 - 2020
  • Associate Professor of Medicine, Neurology, Clinical Science Departments 2006 - 2013
  • Associate Clinical Professor of Medicine, Neurology, Clinical Science Departments 2002 - 2006
• Research
• 

  Selected Grants

  • Deciphering the role of noncoding variation in the pathogenesis of multiple sclerosis awarded by National Institutes of Health 2021 - 2026
  • ECHO MS 2020 awarded by National Multiple Sclerosis Society 2020 - 2022
  • PA Fellowship in Clinical Neuroimmunology awarded by Biogen, Inc. 2017 - 2019
  • An Escalating Multiple Dose Study of ABT-555 in Subjects with Relapsing Forms of Multiple Sclerosis awarded by AbbVie Inc. 2017 - 2018
  • Susceptibility MRI as a marker for diagnosis and clinical disability in MS awarded by National Institutes of Health 2014 - 2017
  • A Phase II, multicenter, randomized, double-blind, parallel gruop, placebo-controlled, adaptive dose-ranging study to eveluate the efficacy and safety of AIN457 (Secuinumab) (IV) inn patients with relapsing mutiple sclerosis. awarded by Novartis Pharmaceuticals Corporation 2013 - 2016
  • Defining the Functional Role of a Novel MS Susceptibility Gene, IL7R alpha chain awarded by National Institutes of Health 2009 - 2015
  • Topic Briefs TO#4_Disease Modifying Therapies on Multiple Sclerosis awarded by Patient Centered Outcomes Research Institute 2015
  • Criterial to Determine Disability Related to Multiple Sclerosis awarded by Agency for Healthcare Research and Quality 2002 - 2004
• 

  External Relationships

  • Alexion Pharmaceuticals, Inc.
  • Biogen Idec Inc.
  • Bristol-Myers Squibb
  • EMD Serono (Merck)
  • Genentech, Inc (Roche Holding)
  • Genzyme Corporation (Sanofi Aventis)
  • Horizon
  • Janssen AI (Johnson & Johnson)
  • Novartis
  • VeraScience
  • vielabio/horizon
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Sutton, Paige, Michael W. Lutz, F Lee Hartsell, Dorlan Kimbrough, N Troy Tagg, Mark Skeen, Nicholas M. Hudak, Christopher Eckstein, and Suma Shah. “Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: Presentation and outcomes of adults at a single center.” J Neuroimmunol 373 (December 15, 2022): 577987. https://doi.org/10.1016/j.jneuroim.2022.577987.
       Full Text  Open Access Copy  Link to Item
    • Masha, Nidhila, Dorlan J. Kimbrough, Christopher P. Eckstein, Nicholas M. Hudak, Mark B. Skeen, F Lee Hartsell, Michael W. Lutz, and Suma Shah. “Neuromyelitis optica: Clinical course and potential prognostic indicators.” Mult Scler Relat Disord 69 (November 19, 2022): 104414. https://doi.org/10.1016/j.msard.2022.104414.
       Full Text  Link to Item
    • Skeen, Mark B. “The Use of Evoked Potentials in Multiple Sclerosis Clinical Trials.” J Clin Neurophysiol 38, no. 3 (May 1, 2021): 161. https://doi.org/10.1097/WNP.0000000000000748.
       Full Text  Link to Item
    • Skeen, Mark B. “Changing Paradigms and Unmet Needs in Multiple Sclerosis: The Role of Clinical Neurophysiology.” J Clin Neurophysiol 38, no. 3 (May 1, 2021): 162–65. https://doi.org/10.1097/WNP.0000000000000749.
       Full Text  Link to Item
    • Skeen, Mark B., and Luca Pani. “Biomarkers and Surrogate End points in Multiple Sclerosis Trials: Regulatory Issues.” J Clin Neurophysiol 38, no. 3 (May 1, 2021): 181–85. https://doi.org/10.1097/WNP.0000000000000732.
       Full Text  Link to Item
    • Yang, Jui-Chen, Shelby D. Reed, Steve Hass, Mark B. Skeen, and F Reed Johnson. “Is Easier Better Than Harder? An Experiment on Choice Experiments for Benefit-Risk Tradeoff Preferences.” Med Decis Making 41, no. 2 (February 2021): 222–32. https://doi.org/10.1177/0272989X20979833.
       Full Text  Link to Item
    • Alschuler, Kevin N., Gloria von Geldern, Darren Ball, Kathleen Costello, Mark Skeen, Salim Chahin, and Annette Wundes. “Rapid transfer of knowledge for multiple sclerosis clinical care during COVID-19: ECHO MS.” Mult Scler Relat Disord 46 (November 2020): 102600. https://doi.org/10.1016/j.msard.2020.102600.
       Full Text  Link to Item
    • Brayo, Petra, F Lee Hartsell, Mark Skeen, Joel Morgenlander, Christopher Eckstein, and Suma Shah. “The clinical presentation and treatment of MOG antibody disease at a single academic center: A case series.” J Neuroimmunol 337 (December 15, 2019): 577078. https://doi.org/10.1016/j.jneuroim.2019.577078.
       Full Text  Link to Item
    • Shah, Suma, Deepal Shah, and Mark B. Skeen. “Recurrent disseminated encephalomyelitis: A case report and literature review.” Mult Scler Relat Disord 26 (November 2018): 86–89. https://doi.org/10.1016/j.msard.2018.09.007.
       Full Text  Open Access Copy  Link to Item
    • Cadavid, Diego, Laura Balcer, Steven Galetta, Orhan Aktas, Tjalf Ziemssen, Ludo Vanopdenbosch, Jette Frederiksen, et al. “Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial.” Lancet Neurol 16, no. 3 (March 2017): 189–99. https://doi.org/10.1016/S1474-4422(16)30377-5.
       Full Text  Link to Item
    • Kolls, Brad J., Daiwai M. Olson, William B. Gallentine, Mark B. Skeen, Christopher T. Skidmore, and Saurabh R. Sinha. “Electroencephalography leads placed by nontechnologists using a template system produce signals equal in quality to technologist-applied, collodion disk leads.” J Clin Neurophysiol 29, no. 1 (February 2012): 42–49. https://doi.org/10.1097/WNP.0b013e318246ae76.
       Full Text  Link to Item
    • Lancaster, Eric, Meizan Lai, Xiaoyu Peng, Ethan Hughes, Radu Constantinescu, Jeffrey Raizer, Daniel Friedman, et al. “Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen.” Lancet Neurol 9, no. 1 (January 2010): 67–76. https://doi.org/10.1016/S1474-4422(09)70324-2.
       Full Text  Link to Item
    • Ferrara, Joseph M., Mark B. Skeen, Nancy J. Edwards, Linda Gray, and E Wayne Massey. “Subacute combined degeneration due to copper deficiency.” J Neuroimaging 17, no. 4 (October 2007): 375–77. https://doi.org/10.1111/j.1552-6569.2007.00126.x.
       Full Text  Link to Item
    • Scherer, Katalin, Mark B. Skeen, Scott A. Strine, and Vern C. Juel. “Hanging leg syndrome: combined bilateral femoral and sciatic neuropathies.” Neurology 66, no. 7 (April 11, 2006): 1124–25. https://doi.org/10.1212/01.wnl.0000204192.09346.c2.
       Full Text  Link to Item
    • McCrory, D. C., L. A. Pompeii, M. B. Skeen, S. D. Moon, R. N. Gray, J. T. Kolimaga, and D. B. Matchar. “Criteria to determine disability related to multiple sclerosis.” Evid Rep Technol Assess (Summ), no. 100 (May 2004): 1–8.
       Link to Item
    • Skeen, Mark B. “Neurologic manifestations of gastrointestinal disease.” Neurologic Clinics 20, no. 1 (February 2002): 195–vii. https://doi.org/10.1016/s0733-8619(03)00059-8.
       Full Text
    • Skeen, M. B., and M. Eggleston. “Thoraconeuralgia gravidarum.” Muscle Nerve 22, no. 6 (June 1999): 779–80. https://doi.org/10.1002/(sici)1097-4598(199906)22:6<779::aid-mus18>3.0.co;2-1.
       Full Text  Link to Item
    • Nohria, V., N. Lee, R. D. Tien, E. R. Heinz, J. S. Smith, G. R. DeLong, M. B. Skeen, T. J. Resnick, B. Crain, and D. V. Lewis. “Magnetic resonance imaging evidence of hippocampal sclerosis in progression: a case report.” Epilepsia 35, no. 6 (1994): 1332–36. https://doi.org/10.1111/j.1528-1157.1994.tb01807.x.
       Full Text  Link to Item
    • Skeen, M. B., M. P. Rozear, and J. C. Morgenlander. “Posey palsy.” Ann Intern Med 117, no. 9 (November 1, 1992): 795. https://doi.org/10.7326/0003-4819-117-9-795_2.
       Full Text  Link to Item
    • Shipman, K. H. “Do restraints prevent falls?” Annals of Internal Medicine 117, no. 5 (September 1992): 442–43. https://doi.org/10.7326/0003-4819-117-5-442.
       Full Text
    • Skeen, M. B. “Do restraints prevent falls?” Ann Intern Med 117, no. 5 (September 1, 1992): 443.
       Link to Item
    • Skeen, M. B. “Wilson disease--penicillamine therapy and late presentation.” Ann Intern Med 116, no. 5 (March 1, 1992): 424. https://doi.org/10.7326/0003-4819-116-5-424_2.
       Full Text  Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.